Jordan U. Gutterman

Jordan U. Gutterman's AcademicInfluence.com Rankings

Jordan U. Gutterman

Philosophy

#4371

World Rank

#6859

Historical Rank

Logic

#1843

World Rank

#2696

Historical Rank

philosophy Degrees

Jordan U. Gutterman

Biology

#5692

World Rank

#8233

Historical Rank

Molecular Biology

#531

World Rank

#544

Historical Rank

Biochemistry

#697

World Rank

#797

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Jordan U. Gutterman's Degrees

PhD Molecular Biology University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Jordan U. Gutterman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jordan U. Gutterman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Synthesis of Messenger RNAs for Transforming Growth Factors α and β and the Epidermal Growth Factor Receptor by Human Tumors (1987) (916)
The molecular genetics of Philadelphia chromosome-positive leukemias. (1988) (854)
The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis (2007) (850)
Alpha interferon for induction of remission in hairy-cell leukemia. (1984) (822)
Cytokine therapeutics: lessons from interferon alpha. (1994) (695)
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. (1986) (692)
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. (1987) (599)
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. (1980) (486)
Phase I study of recombinant tumor necrosis factor in cancer patients. (1987) (461)
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. (1991) (402)
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. (1982) (378)
Clinical investigation of human alpha interferon in chronic myelogenous leukemia. (1987) (350)
Renal cell carcinoma: antitumor effects of leukocyte interferon. (1983) (332)
13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin (1992) (326)
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. (1983) (315)
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. (1979) (281)
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia (1987) (279)
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. (1985) (262)
Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. (1984) (245)
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. (1988) (226)
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. (1974) (225)
Active immunotherapy with B.C.G. for recurrent malignant melanoma. (1973) (223)
Treatment of hairy cell leukemia with recombinant α-interferon (1986) (216)
Avicins: Triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation (2001) (198)
Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. (1988) (190)
Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant γ-lnterferon in Cancer Patients (1985) (179)
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. (1985) (178)
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. (1974) (175)
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. (1987) (172)
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. (1992) (165)
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-κB by inhibiting both its nuclear localization and ability to bind DNA (2001) (164)
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. (1977) (154)
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. (1990) (153)
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. (1974) (151)
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. (2001) (141)
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. (1997) (136)
Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. (2001) (134)
PSORIASIS AND ALPHA-INTERFERON (1986) (134)
Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. (1988) (133)
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. (1982) (132)
Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. (1993) (126)
Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. (1996) (125)
RANDOMIZED TRIAL OF PROTECTED ENVIRONMENT — PROPHYLACTIC ANTIBIOTICS IN 145 ADULTS WITH ACUTE LEUKEMIA (1978) (125)
Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. (1988) (124)
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia (1991) (123)
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. (1973) (114)
Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa‐2a by intramuscular injection (1987) (108)
Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. (1984) (106)
Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas (2001) (104)
Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. (1985) (104)
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. (1989) (102)
Expression of the macrophage colony‐stimulating factor and its receptor in gynecologic malignancies (1991) (102)
Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (101)
Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. (1988) (101)
A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase (2007) (101)
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. (1992) (100)
Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. (1985) (100)
ANTIBODIES TO HUMAN LEUCOCYTE INTERFERONS IN CANCER PATIENTS (1983) (99)
Treatment of multiple myeloma with recombinant alpha-interferon (1986) (97)
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial (1985) (97)
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. (1985) (95)
Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. (1987) (95)
Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. (1986) (95)
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study. (1989) (94)
Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. (1983) (94)
Inhibition of drug-metabolizing enzymes in the rat after Bacillus Calmette-Guérin treatment. (1976) (93)
Cytokine therapeutics: Lessons from interferon a (92)
Human Cytokines: Handbook for Basic and Clinical Research (1996) (92)
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. (1987) (91)
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity (1991) (90)
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. (1990) (90)
Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery. (2004) (88)
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model (2001) (87)
Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. (1987) (86)
Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. (1986) (86)
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. (1987) (86)
Pharmacokinetic study of partially pure gamma-interferon in cancer patients. (1984) (84)
Treatment of hairy cell leukemia with recombinant alpha-interferon. (1986) (84)
Oncogene expression in human leukemia. (1984) (83)
Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. (1974) (79)
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. (1976) (77)
Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. (1991) (77)
Leukocyte Interferon in Patients with Juvenile Laryngeal Papillomatosis (1982) (76)
Chronic myelogenous leukaemia: haematological remissions with alpha interferon (1986) (76)
Effects of low doses of recombinant human granulocyte‐macrophage colony stimulating factor (GM‐CSF) in patients with myelodysplastic syndromes (1991) (75)
PROLONGATION OF POSTOPERATIVE DISEASE-FREE INTERVAL AND SURVIVAL IN HUMAN COLORECTAL CANCER BY B.C.G. OR B.C.G. PLUS 5-FLUOROURACIL (1976) (75)
Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients (1986) (74)
In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase. (1986) (74)
Inhibition of E2F-4/DP-1-stimulated transcription by p202 (1997) (72)
Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. (1988) (72)
CHEMOIMMUNOTHERAPY OF ADULT ACUTE LEUKÆMIA (1975) (71)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (70)
Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. (1989) (69)
Antigen solubilized from human solid tumours: lymphocyte stimulation and cutaneous delayed hypersensitivity. (1973) (68)
Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. (1988) (68)
Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. (1989) (68)
Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer (1978) (68)
Therapy of chronic myelogenous leukemia: chemotherapy and interferons. (1988) (66)
Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. (1986) (65)
IMMUNOCOMPETENCE, IMMUNODEFICIENCY AND PROGNOSIS IN CANCER * (1976) (65)
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. (1992) (65)
Modification of human leukocyte interferon pharmacology with a monoclonal antibody. (1985) (63)
Avicins, natural anticancer saponins, permeabilize mitochondrial membranes. (2006) (62)
Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. (2007) (61)
Human leukocyte interferon preparation blocks granulopoietic differentiation (1979) (60)
Isolation and structures of avicins D and G: in vitro tumor-inhibitory saponins derived from Acacia victoriae. (2003) (60)
Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. Granulosum and C. Parvum (1974) (59)
Nodular malignant lymphomas. Factors affecting complete response rate and survival (1979) (58)
Treatment of hairy cell leukemia with alpha interferons (1986) (58)
CHOP-Bleo plus interferon for stage IV low-grade lymphoma. (1993) (57)
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. (1992) (56)
Immune Thrombocytopenia Following α-Interferon Therapy in Patients With Cancer (1985) (55)
BCG as adjuvant immunotherapy for neoplasia. (1977) (55)
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia (1988) (55)
Intensive chemotherapy induction followed by interferon‐alpha maintenance in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia (1991) (53)
Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. (1989) (53)
Increased incidence of hypersensitivity to iodine‐containing radiographic contrast media after interleukin‐2 administration (1990) (53)
Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. (1985) (53)
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia (1987) (52)
Proapoptotic triterpene electrophiles (avicins) form channels in membranes: cholesterol dependence. (2005) (50)
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. (1991) (50)
Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-alpha. (1982) (50)
Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia‐a pilot study (1987) (50)
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) (1979) (49)
Avicin D, a Plant Triterpenoid, Induces Cell Apoptosis by Recruitment of Fas and Downstream Signaling Molecules into Lipid Rafts (2009) (49)
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. (1988) (48)
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. (1979) (48)
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. (1991) (48)
Lymphocyte blastogenesis to human leukemia cells and their relationship to serum factors, immunocompetence, and prognosis. (1972) (47)
Human leukocyte interferon preparation blocks granulopoietic differentiation. (1979) (47)
Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients. (1983) (47)
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. (2008) (47)
Bcl-1 gene rearrangements in B cell lymphoma. (1988) (47)
Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. (1988) (46)
Mechanisms of combined effects of gamma-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. (1989) (45)
Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients. (1986) (45)
Molecular characteristics of chronic myelogenous leukemia in blast crisis. (1987) (45)
Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. (1982) (44)
Down‐regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFNα) therapy (1985) (44)
Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future. (1975) (44)
Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient. (1976) (44)
Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. (1993) (44)
Effect of glucan on natural killer (NK) cells: further comparison between NK cell and bone marrow effector cell activities. (1979) (43)
Avicinylation (thioesterification): a protein modification that can regulate the response to oxidative and nitrosative stress. (2005) (43)
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. (1993) (43)
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. (1992) (43)
Antigen Solubilized from Human Leukemia: Lymphocyte Stimulation (1972) (42)
BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report (1973) (42)
Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. (1988) (42)
Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. (1988) (41)
Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). (1983) (41)
IMMUNE INTERFERON DOES NOT STIMULATE FORMATION OF ALPHA AND BETA INTERFERON INDUCED HUMAN LUPUS-TYPE INCLUSIONS (1983) (39)
Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells (1986) (39)
Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study. (1976) (38)
Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. (1993) (38)
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. (1992) (38)
Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. (1990) (37)
Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients (1991) (37)
Triterpenoid Electrophiles (Avicins) Suppress Heat Shock Protein-70 and X-Linked Inhibitor of Apoptosis Proteins in Malignant Cells by Activation of Ubiquitin Machinery: Implications for Proapoptotic Activity (2005) (37)
Human leukocyte interferon preparation-mediated block of granulopoietic differentiation in vitro. (1981) (37)
Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases (1992) (37)
Interferon treatment for multiple myeloma. (1982) (37)
Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202 (1999) (36)
Retardation of cell proliferation after expression of p202 accompanies an increase in p21(WAF1/CIP1). (1999) (35)
Avicin D: A Protein Reactive Plant Isoprenoid Dephosphorylates Stat 3 by Regulating Both Kinase and Phosphatase Activities (2009) (35)
Detection of immune complex-like materials in cancer patients' sera: a comparative study of results obtained with the C1q deviation and C1q binding tests. (1978) (35)
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival (1977) (34)
Therapy of chronic myelogenous leukemia (1987) (33)
Impaired in vitro interferon, blastogenic, and natural killer cell responses to viral stimulation in acquired immune deficiency syndrome. (1985) (33)
Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons (1988) (33)
Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma (1979) (33)
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. (1992) (33)
Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. (1992) (32)
IN VITRO AND IN VIVO STUDIES WITH THYMOSIN IN CANCER PATIENTS * (1976) (31)
Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. (1983) (31)
Chronic myelogenous leukemia--past, present, and future. (1988) (31)
Immunotherapy of Cancer in Man (1973) (31)
p202 prevents apoptosis in murine AKR-2B fibroblasts. (1998) (30)
Effect of differentiation‐inducing agents on oncogene expression in a chronic myelogenous leukemia cell line (1988) (30)
Corynebacterium parvum: Preliminary Report of a Phase I Clinical and Immunological Study in Cancer Patients (1975) (30)
Red blood cell permeabilization by hypotonic treatments, saponin, and anticancer avicins. (2010) (30)
Cell-mediated immunity to human solid tumors: in vitro detection by lymphocyte blastogenic responses to cell-associated and solubilized tumor antigens. (1973) (30)
Stimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating factor. (1990) (29)
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results (1975) (29)
BCG Stimulation of Immune Responsiveness in Patients with Malignant Melanoma (1974) (29)
Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole (1979) (28)
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies. (1986) (28)
Treatment of multiple myeloma with recombinant alpha-interferon. (1986) (28)
Melphalan therapy of polycythemia vera. (1970) (27)
Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. (1983) (27)
Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. (1986) (27)
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients. (1986) (27)
Effects of the tumor inhibitory triterpenoid avicin G on cell integrity, cytokinesis, and protein ubiquitination in fission yeast. (2005) (27)
Multifaceted Evaluation of Human Tumor Immunity Using a Salt Extracted Colon Carcinoma Antigen 1 (1972) (27)
Effect of recombinant human interleukin 4 on human monocyte activity. (1990) (26)
Update on therapeutic options for chronic myelogenous leukemia. (1990) (26)
Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status. (1974) (26)
Prolonged remissions in adults with acute leukemia following late intensification chemotherapy and immunotherapy (1981) (26)
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia (1992) (26)
Chemoimmunotherapy for multiple myeloma (1981) (25)
Antibodies to melanoma cell and BCG antigens in sera from tumour-free individuals and from melanoma patients (1976) (25)
Separation of viable from non-viable tumor cells using Ficoll-Hypaque density solution. (1973) (25)
Production of Interferon-α Induced by dsRNA in Human Peripheral Blood Mononuclear Cell Cultures: Role of Priming by dsRNA-Induced Interferons-γ and -β (1989) (25)
Interferons in the treatment of human neoplasms. (1987) (25)
Alpha-interferon combination therapy of resistant myeloma. (1991) (25)
Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines (1987) (25)
HLA antigens and immunoglobulin allotypes in patients with malignant melanoma. (1981) (24)
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. (1987) (24)
Immunotherapy of cancer in man : scientific basis and current status (1973) (24)
Phase I and II studies of the combination of recombinant human interferon-γ and 5-fluorouracil in patients with advanced colorectal carcinoma (1989) (24)
Antibody‐dependent cell‐mediated cytotoxicity in human cancer: Characterization of patient leukocyte activity and treatment effects (1982) (23)
Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection (1994) (23)
Immunodiagnosis of acute leukemia: detection of residual disease. (1974) (23)
Recall antigen delayed-type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates. (1979) (23)
Synergistic antiproliferative activity of leukocyte interferon in combination with alpha-difluoromethylornithine against human cells in culture. (1984) (23)
Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. (1987) (23)
Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. (1990) (23)
The Anticancer Plant Triterpenoid, Avicin D, Regulates Glucocorticoid Receptor Signaling: Implications for Cellular Metabolism (2011) (23)
Host defense, chemical immunosuppression, and the transplant recipient. Relative effects of intermittent versus continuous immunosuppressive therapy with reference to the objectives of treatment. (1973) (22)
BCG Vaccine and Its Derivatives: Potential, Practical Considerations, and Precautions in Human Cancer Immunotherapy (1976) (22)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (22)
Suppression of chronic myelogenous leukemia colony growth by interleukin-4. (1993) (21)
p202 self‐associates through a sequence conserved among the members of the 200‐family proteins (1998) (21)
Nephrotoxicity from cancer immunotherapy. (1978) (21)
Phase I Study of a Combination of Recombinant Tumor Necrosis Factor-α and Recombinant Interferon-γ in Cancer Patients (1989) (21)
A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. (1990) (21)
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. (1987) (21)
Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor gene. (1988) (20)
Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer (1979) (20)
Human leukocyte interferon‐mediated granulopoietic differentiation arrest and its abrogation by lithium carbonate (1982) (19)
Effect of haematological malignancies and their treatment on host defence factors. (1976) (19)
Natural triterpenoid avicins selectively induce tumor cell death (2010) (19)
IMMUNOTHERAPY OF HUMAN SOLID TUMORS WITH BACILLUS CALMETTE‐GUÉRIN: PROLONGATION OF DISEASE‐FREE INTERVAL AND SURVIVAL IN MALIGNANT MELANOMA, BREAST, AND COLORECTAL CANCER * (1976) (19)
Human immune response to active immunization with Rauscher leukemia virus. II. Humoral immunity. (1974) (19)
Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer (1991) (19)
The interferon-inducible growth-inhibitory p202 protein: DNA binding properties and identification of a DNA binding domain. (1996) (19)
Mid-term observations on the efficacy of alpha-interferon in hairy cell leukemia and status of the interferon system of patients in remission. (1987) (19)
Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer. (1981) (18)
Evaluation of BCG administered by scarification for immunotherapy of metastatic hepatocarcinoma in the guinea pig. (1976) (18)
Immunochemotherapy of human cancer. (1974) (18)
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. (1991) (18)
Mitochondria as integrators of information in an early-evolving animal: insights from a triterpenoid metabolite (2005) (18)
Intravascular Hemolysis in a Patient with Valvular Heart Disease (1966) (18)
Chemoimmunotherapy of human solid tumors. (1976) (17)
Effect of immunotherapy with Corynebacterium parvum and methanol extraction residue of BCG administered intravenously on host defense function in cancer patients. (1981) (17)
Cell-mediated and humoral immune response to acute leukemia cells and soluble leukemia antigen--relationship to immunocompetence and prognosis. (1973) (17)
Molecular analysis of chromosome 22 breakpoints in adult Philadelphia‐positive acute lymphoblastic leukaemia (1987) (17)
Fetal antigens in human leukemia. (1976) (16)
Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte‐macrophage colony‐stimulating factor (1990) (16)
Treatment of cyclic neutropenia with very low doses of GM-CSF. (1991) (16)
Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon (1985) (16)
ALPHA INTERFERONS IN B‐CELL NEOPLASMS (1986) (16)
Cancer and host defense mechanisms. (1975) (16)
Metabolomics of plant saponins: bioprospecting triterpene glycoside diversity with respect to mammalian cell targets. (2002) (16)
The role of interferons in the treatment of hematologic malignancies. (1988) (16)
Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens. (1988) (16)
IMMUNOLOGIC STUDIES OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME: RELATIONSHIP OF IMMUNODEFICIENCY TO EXTENT OF DISEASE a (1984) (15)
Disseminated bcg disease associated with immunotherapy by scarification in acute leukemia (1978) (15)
Characterization of human recombinant tumor necrosis factor-alpha antiproliferative effects on human cells in culture. (1988) (15)
Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies (2004) (15)
Glycosylation facilitates transdermal transport of macromolecules (2012) (15)
A Phase‐I Clinical Study of Low‐Dose Oral Interferon-α (1993) (15)
Specific and non‐specific immunologic reactivity of regional lymph‐node lymphocytes in human malignancy (1974) (15)
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. (1993) (15)
Immunotherapy of human cancer. (1977) (14)
Immunotherapy as related to lung cancer: a review. (1974) (14)
Permanent slide preparations of T lymphocyte-sheep red blood cell rosettes. (1975) (14)
Recent advances in the therapy of chronic myelogenous leukemia. (1988) (14)
Biologic therapy of hairy cell leukemia. (1984) (14)
Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG. (1975) (14)
Hairy cell leukaemia: review of treatment (1991) (14)
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial (1987) (14)
ANTIGEN EXPRESSION AND CELL SURFACE PROPERTIES OF HUMAN LEUKEMIC BLASTS * (1976) (14)
New agents and combination chemotherapy of non-Hodgkin's lymphoma. (1975) (13)
Chemoimmunotherapy of disseminated malignant melanoma with DTIC‐BCG, transfer factor + melphalan (1980) (13)
An effective new chemoimmunotherapy regimen for disseminated malignant melanoma (DMM) (1977) (13)
Interaction between repeated skin testing with recall antigens and temporal fluctuations of in vitro lymphocyte blastogenesis in cancer patients. (1977) (13)
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. (1976) (13)
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (1997) (13)
Sialic Acid on Leukemia Cells: Relation to Morphology and Tumor Immunity (1974) (13)
Combination chemoimmunotherapy for extensive non-oat cell lung cancer. (1978) (12)
Phase 2 study with Baker's Antifol in solid tumors. (1977) (12)
Leukocyte interferon (IF) induced tumor regression in patients (pts) with breast cancer and B cell neoplasms (1979) (12)
Further Observations on the Treatment of Recurrent Respiratory Papillomatosis with Interferon: A Comparison of Sources (1983) (12)
Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. (1978) (12)
Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival. (1979) (12)
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma. (1980) (11)
Immunotherapy of leukemia. (1976) (11)
Evaluation of vindesine and MER in colorectal cancer (1980) (11)
Immune reactivity of lymphoid tissues adjacent to carcinoma of the ascending colon. (1974) (11)
Glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. (1978) (11)
Alpha interferon production in patients with hairy cell leukemia: correlations with disease activity and remission status. (1987) (10)
Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma. (1989) (10)
Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. (1987) (10)
A Rapid Method for Establishing Short-Term Primary Cultures of Human Tumor Cells from Fresh Tumor Biopsies (1975) (10)
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia. (1986) (10)
Actinomycin‐D plus 5‐(3,3‐dimethyl‐ 1‐triazeno)‐ imidazole‐4‐carboxamine (DTIC) with or without intravenous corynebacterium parvum in metastatic malignant melanoma (1982) (10)
Complement activation in vivo in cancer patients receiving C. parvum immunotherapy. (1976) (10)
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. (1987) (10)
Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia (1978) (10)
Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling (2020) (10)
Recombinant human retinoblastoma protein inhibits cancer cell growth. (1995) (10)
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. (1980) (9)
Interferon-α-Induced Human Lupus Inclusions and p36 Protein in Cancer and AIDS (1996) (9)
Approaches to the study of tumor antigens and tumor immunity in malignant melanoma (1975) (9)
A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinum (1991) (9)
Production of interferon-alpha induced by dsRNA in human peripheral blood mononuclear cell cultures: role of priming by dsRNA-induced interferons-gamma and -beta. (1989) (9)
Head and neck squamous cell carcinoma cell lines as a model system for the study of oncogene expression during tumor progression and metastasis. (1986) (9)
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. (1991) (9)
Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center (1989) (9)
Therapy of chronic myelogenous leukemia with interferon. (1989) (9)
Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule. (1973) (9)
Mononuclear cell content of human solid tumors. (1976) (8)
Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer (1977) (8)
Cancer systemic active immunotherapy today — prospects for tomorrow (1977) (8)
Primary brain tumors: tumor immunity and immunocompetence. (1973) (8)
Effect of BeG (lice Strain) on Primary Sensitization to 2,4-Dinitrochlorobenzene and on Established Delayed Hypersensitivity in Human Malignant Melanoma (1976) (8)
Therapy of chronic myelogenous leukaemia with interferons. (1989) (8)
Studies on the Mode of Action of N-Isopropyl-α-(2-methylhydrazino)-p-toluamide (MIH) (1969) (8)
Treatment of Multiple Myeloma With Recombinant a-Interferon (2005) (8)
Biologic therapy of chronic myelogenous leukemia. (1987) (7)
Human immune response to active immunization with Rauscher leukemia virus. I. Cell-mediated and cell-associated immunity. (1974) (7)
Adjuvant Chemotherapy and Immunotherapy in Colorectal Cancer (1978) (7)
Tumor necrosis factor and human hematopoiesis: II. Inhibition and mode of action on normal and chronic myelogenous leukemia-derived granulocyte-macrophage progenitor cells. (1988) (7)
Histiocytic lymphoma in the brain as the only manifestation of relapse following remission maintainance with BCG immunotherapy (1977) (7)
Diagnosis of malaria by bone marrow aspiration. (1972) (7)
IMMUNOTHERAPY OF HUMAN SOLID TUMORS: PROLONGATION OF DISEASE-FREE INTERVAL AND SURVIVAL IN MALIGNANT MELANOMA, BREAST AND COLORECTAL CANCER (1976) (7)
Active specific immunization in malignant melanoma. (1975) (7)
Immunological evaluation of malignant disease. Diagnosis, prognosis, and management. (1976) (7)
Current Status of Human Cancer Immunotherapy (1981) (6)
Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A. (1983) (6)
Research Funding: Clinical investigators: The driving force behind drug discovery (1997) (6)
Perspectives in immunotherapy of lung cancer. (1974) (6)
Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons. (1988) (6)
Immunoglobulins on the surface of human appendix lymphocytes. (1974) (6)
Pulmonary abnormalities in patients intravenously receiving the methanol extraction residue (MER) of bacillus calmette‐guerin (1980) (5)
Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study. (1988) (5)
Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin. (1977) (5)
Chemo immunotherapy of advanced breast cancer with BCG. (1977) (5)
Antitumor effects of partially pure human leukocyte interferon in renal cell carcinoma (1982) (5)
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. (1989) (5)
Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. (1988) (5)
Induction of proteins in human lymphoblastoid cells by recombinant alpha interferon. (1984) (5)
Subpopulations of thymus dependent and thymus independent lymphocytes in human gut associated lymphoid tissues. (1975) (5)
Phase I–II study of intratumor immunotherapy with BCG cell wall skeleton plus P3 (1978) (5)
Suppression of c-myc and c-myb expression in myeloid cell lines treated with recombinant tumor necrosis factor-alpha. (1988) (5)
Measurement of effects of human leukocyte interferon on human granulocyte colony-forming cells in vitro. (1981) (4)
Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. (1981) (4)
High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine. (1985) (4)
Interferons and cell growth regulation. (1984) (4)
Pseudomonas vaccine: A phase I evaluation for cancer research (1978) (4)
Specific Colony Inhibition by Human Lymphoma Cells on an Established Human Lymphoma Cell Line (1973) (4)
In Vivo Biologic Activities of Recombinant Human Granulocyte‐Macrophage Colony‐Stimulating Factor (1989) (4)
Immunostimulation with different BCG preparations during immunochemotherapy of melanoma (1976) (3)
α‐Interferon Combination Therapy of Resistant Myeloma (1991) (3)
LYMPHOMA-ASSOCIATED AND HL-A ANTIGENS IN THE MIXED LEUKOCYTE REACTIVITY BETWEEN IDENTICAL SIBLINGS (1973) (3)
Immunology and Immunotherapy of Human Breast Cancer (1977) (3)
A phase I study of recombinant DNA produced leukocyte interferon by an intermittent schedule (1982) (3)
Effect of Recombinant Tumor Necrosis Factor a in vitro and Its Modulation by a and y Interferons (2005) (3)
Remission induction of adult acute leukemia with combination chemotherapy (1971) (3)
Novel therapeutic approaches for chronic myelogenous leukemia (1990) (3)
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. (1990) (3)
Activity of human leukocyte interferon in a human tumor cloning system (2004) (3)
Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma. (1976) (3)
Cardiac arrhythmia in a CML patient treated with interferons. (1989) (3)
Cytokines in tumor therapy. Interleukin-3. (1991) (3)
Chemoimmunotherapy of human cancer: The need for a unified drug development program (1978) (3)
Immunotherapy of human solid tumours: principles of development (1978) (3)
Phase I toxicity study of methanol-extracted residue of Bacillus Calmette-Guérin by the iv route. (1979) (3)
Avicins: A Novel Class of Anti-Myeloma Agents. (2004) (3)
Surface proteins of human acute myelogenous leukemia (AML) cells (1975) (3)
Aberrant expression of the K-ras proto-oncogene in B-cell malignancies. (1988) (3)
Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS. (1996) (3)
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. (1989) (3)
Cell-Mediated Immunity to Plasma Cell Myeloma: Specific Inhibition by a Serum Factor Adhering to Effector Lymphocytes 1 (1974) (3)
Cytogenetic changes induced by 1-(N1-methylhydrazinomethyl)-N-isopropyl benzamide in Ehrlich ascites tumor cells (1969) (2)
Preclinical and clinical effects of the hematopoietic colony stimulating factors. (1988) (2)
Treatment of acute myelogenous leukemia with chemotherapy and hematopoietic growth factors (1990) (2)
Partial restoration by in vivo thymosin of E-rosettes and delayed-type hypersensitivity reactions in immunodeficient cancer patients (1976) (2)
Human immune response to Rauscher leukemia virus. (1974) (2)
Clinical pharmacology of dacarbazine (DIC) following intensive corynbecterium parvum (CP) immunotherapy (1977) (2)
Clinical Investigation of Interferons: Status Summary and Prospects for the Future (1984) (2)
The Lasker Awards at fifty. (1995) (2)
Leukocyte interferon induces tumor regression in patients with breast cancer and B cell neoplasms (1979) (2)
Recreating an environment for clinical discovery. (1997) (2)
ANERGY IN CANCER (1976) (2)
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. (1990) (2)
Can natural selection and druggable targets synergize? Of nutrient scarcity, cancer, and the evolution of cooperation (2020) (2)
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer (1979) (2)
Tumor necrosis factor and human hematopoiesis: I. Kinetics and diversity of human bone marrow cell response to recombinant tumor necrosis factor alpha in short-term suspension cultures in vitro. (1988) (2)
A phase-I clinical study of low-dose oral interferon-alpha. (1993) (2)
Biologic therapy of human cancer. (1992) (2)
Human leukocyte interferon (IFN) and mismatched, double-stranded RNA (dsRNA): synergistic antiproliferative activity in vitro (1985) (2)
The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma (1979) (1)
Differential cell cycle response of normal and tumor human cells to interferon treatment (1979) (1)
Some host defense modifying effects of intravenous microbial adjuvants (1979) (1)
Expression of p21(ras) in fresh primary human lung tumors (1985) (1)
Initial clinical trials with arabinosyl-6-mercaptopurine (1975) (1)
Chemoimmunotherapy of disseminated malignant melanoma (DMM) with DTIC, BCG, transfer factor (TF) ± Melphalan (L-PAM) (1977) (1)
Therapeutic Potential of a Desert Plant Triterpenoid Molecule for Polycythemia Vera. (2006) (1)
The effects of intravenous administration of Methanol Extraction Residue (MER) of tubercle bacilli in the dog (2004) (1)
Leukocyte interferon conjugated to beta-D-galactosidase for receptor studies: a preliminary report. (1985) (1)
Cancer Systemic Active Prospects for Tomorrow (1977) (1)
Cancer immunotherapy. (1979) (1)
Rationale and application of immunotherapy for human cancer (1978) (1)
Adjuvant therapy of stage II, III breast cancer. (1978) (1)
INTERFERON Α2B AS ANTI-ANGIOGENESIS THERAPY OF GIANT CELL TUMOR OF BONE (1999) (1)
Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma. (1982) (1)
BCG immunotherapy for recurrent malignant melanoma (1980) (1)
Tumor-related blocking of anti-fetal immunity. (1977) (1)
Organ distributions and clearance studies of 99mtechnetium-labeled Corynebacterium parvum in patients with leukemia. (1981) (1)
An intensive new adjuvant chemoimmunotherapy program containing 5 fluorouracil (5 FU), adriamycin (AD), cyclophosphamide (CYT), and BCG (FAC BCG) for operable breast cancer (1977) (1)
The Myeloprotective Effect of Recombinant Human Granulocyte‐Macrophage Colony‐stimulating Factor Given Sequentially with Continuous Infusion Vinblastine in Metastatic Breast Cancer Patients (1993) (1)
Expression of p21ras Gene Products in Fresh Primary and Metastatic Human Tumor Tissue (1986) (1)
Biologic agents for the management of hematological disorders: chronic myeloid leukemia. (1987) (1)
Its possible application in the management of large-bowel cancer (1974) (1)
Toxicity of BCG administered by scarification to cancer patients (1978) (1)
Recall antigen delayed-type hypersensitivity skin testing: standardization of self-reading by patients (1979) (1)
Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions (1977) (1)
Prolongation of disease-free and overall survival with the adjuvant FAC-BCG in stage II, III breast cancer (1979) (1)
Immune Thrombocytopenia After α-Interferon Therapy in Patients With Cancer-Reply (1986) (1)
Phase I study of intratumor (II) immunotherapy with BCG cell wall skeleton plus P3 (CWS/P3) (1977) (1)
Assessment of immunocompetence in the routine evaluation of the cancer patient. (1976) (1)
Phase I study of immunotherapy with methanol extraction residue of BCG (MER) administered by the intravenous (IV) route (1980) (1)
Activation of 2′,5′-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: Dependence of biological effect on administration route (1986) (1)
Prolongation of post operative tumor free interval and survival in colorectal cancer by adjuvant BCG or BCG + 5 FU (1976) (1)
Biological response modifiers in the treatment of hematopoietic neoplasia (1992) (1)
Histological Subtypes of Fresh Primary Human Lung Tumors Differential Expression of p21ras Gene Products among (2013) (0)
Differential patterns of human natural killing and its modulation by interferon (1980) (0)
Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia (1988) (0)
Abstract 1033: The anticancer compound avicin D targets lysosomal functions (2021) (0)
Triterpenzusammensetzungen and their use methods (1999) (0)
Chemotherapy and immunotherapy for malignant melanoma. (1980) (0)
Effect of Recombinant Human Interleukin 4 on Human Monocyte Activity 1 (2006) (0)
Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG (1975) (0)
Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant 7-lnterferon in Cancer Patients1 (2006) (0)
Hematologic Malignancies : Lessons from Hairy Cell Leukemia (0)
Chemoimmunotherapy of advanced breast cancer. (1976) (0)
A process for preparing antikoerperzusammensetzungen of therapeutic agents with extended serum half-life. (1984) (0)
Three catalytic lives linked by the Lasker Awards (2008) (0)
Interleukin-3 (1991) (0)
Contents, Vol. 42, Supplement 1, 1985 (1985) (0)
Dacarbazine (DIC) clinical pharmacology: effects of intensive Corynebacterium parvum (CP) immunotherapy and actinomycin D (ACT D) (1977) (0)
Efficacy of Alpha Interferons in Hairy Cell Leukemia (HCL) and Status of the Interferon System of Patients in Remission (1987) (0)
Idiotypic cross-reactivity among murine monoclonal antibodies to recombinant human leukocyte A interferon (1985) (0)
Antikroppkompositioner of therapeutic efficacy aemnen Vilka har foerlaengd halveringstid i blodserumet. (1985) (0)
Letter: Treatment of malignant melanoma. (1974) (0)
Compositions de triterpene et leurs champ d'application (1999) (0)
Immunotherapy with intravenous (IV) C. parvum (CP), nephrotoxicity (1977) (0)
Interaction of human malignant melanoma cells with a microbial immunotherapeutic agent (1977) (0)
Therapeutic antistofpraeparater with extended serum half-life (1985) (0)
Carcinomas of the Head and Neck Activity in Human Cell Lines Established from Squamous Epidermal Growth Factor Receptor Protein-Tyrosine Kinase Updated (2006) (0)
Mice 5-Fluorouracil on Human Colon Cancers Implanted into Nude-Interferon and γ Mechanisms of Combined Effects of Updated Version (2006) (0)
Role of BCG immunotherapy in malignant disease. (1975) (0)
Foerfarande Foer framstaellning of a terapeutiskt anvaendbar interferon anti-interferon-antikropp complexes. (1985) (0)
Evaluation of therapy with methanol extraction residue of BCG (MER) (1982) (0)
Clinical and biological activity of the interferons in hematologic malignancies. (1989) (0)
Synergistic activity of biologic response modifier combinations (1985) (0)
Renal Cell Carcinoma: Antitumor Effects of Leukocyte Interferon 1 (2007) (0)
Phase 1 Clinical Investigation of 4 '-( 9-Acridmylammo ) methanesulfon-m-anisidide ( NSC 249992 ) , a New Acridine Derivative 1 (2006) (0)
Analysis of PllO * " " " " * ' Tyrosine Protein Kinase Activity in Various Subtypes of Philadelphia Chromosome-positive Cells from Chronic Myelogenous Leukemia Patients 1 (2006) (0)
Combined modality therapy of malignant melanoma (1979) (0)
A Plant Triterpenoid Avicin D Stimulates Adipocytic Differentiation of Bone Marrow Stromal Cells and Promotes Their Pro-Survival Effects On Acute Monoblastic Leukemia Cells (2012) (0)
Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling (2020) (0)
The antineoplastic effect of Corynebacterium parvum modified by lysozyme treatment (1980) (0)
Brief communication: Specific colony inhibition by human lymphoma cells on an established human lymphoma cell line. (1973) (0)
Synergistic effects of avicins and hydroperoxides on mitochondria: a possible mechanism for the selective killing of cancer cells (2007) (0)
In vitro and in vivo evaluation of macrophage function in man (1976) (0)
Human Tumors and the Epidermal Growth Factor Receptor by β and α Factors Synthesis of Messenger RNAs for Transforming Growth (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jordan U. Gutterman?

Jordan U. Gutterman is affiliated with the following schools:

Jordan U. Gutterman's Academic­Influence.com Rankings

Jordan U. Gutterman's Degrees

Why Is Jordan U. Gutterman Influential?

Jordan U. Gutterman's Published Works

Published Works

What Schools Are Affiliated With Jordan U. Gutterman?

Jordan U. Gutterman's AcademicInfluence.com Rankings